MarketPeel
Insider Trading Intelligence
PT

Paul Peter Tak

CADL
CHIEF EXECUTIVE OFFICER · CANDEL THERAPEUTICS, INC. · CIK 0001873905
FILING MIX · LIFETIME55%/45%
BUYS
11
SELLS
9
TOTAL VALUE
$1.54M
COMPANIES
1
ACTIVE SINCE
Jul 2021
HOLDINGS NOW
629,000
AVG SELL PX
$5.33
TRADE KIND
SHOWING 20 / 20
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
10 backtested trades · 8 horizons · 7 pending
Forward-return performance of every backtestable P/S trade by Paul Peter Tak, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d10+60.00%-5.16%+0.02%-5.18%-4.65%
14d10+60.00%-9.50%-0.42%-9.08%-13.58%
30d10+70.00%-3.02%-1.51%-1.51%-0.94%
60d10+60.00%+6.38%+1.29%+5.10%+10.26%
90d10+70.00%-5.25%-0.08%-5.17%-15.07%
180d10+40.00%-12.04%+7.36%-19.40%-22.93%
1y10+50.00%-31.20%+14.21%-45.41%-53.05%
2y10(7 pending)+66.67%+75.51%+41.03%+34.48%+83.34%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
CADL · 629,000 shares · as of Jan 26, 2026
0440,992881,9841,322,9761,763,96820222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 11 buys / 9 sellsCOVERAGE · 19 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
CADL
CANDEL THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
629,000629,000Jan 26, 2026Jan 28, 2026View →
CADL
CANDEL THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
42,826$4.67$200.0K268,566Jun 25, 2025Jun 26, 2025View →
CADL
CANDEL THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
400$9.00$3.6K225,740Mar 19, 2025Mar 20, 2025View →
CADL
CANDEL THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
25,772$8.77$226.0K226,140Mar 18, 2025Mar 20, 2025View →
CADL
CANDEL THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
525,000525,000Feb 12, 2025Feb 14, 2025View →
CADL
CANDEL THERAPEUTICS, INC.
SALE
Chief Executive Officer
21,704$7.23$156.8K251,912Jan 15, 2025Jan 17, 2025View →
CADL
CANDEL THERAPEUTICS, INC.
SALE
Chief Executive Officer
21,172$8.22$174.0K273,616Jan 8, 2025Jan 10, 2025View →
CADL
CANDEL THERAPEUTICS, INC.
SALE
Chief Executive Officer
48,847$4.56$222.5K294,788Nov 29, 2024Dec 3, 2024View →
CADL
CANDEL THERAPEUTICS, INC.
PURCHASE
Chief Executive Officer
12,900$1.55$20.0K343,635Nov 21, 2024Nov 21, 2024View →
CADL
CANDEL THERAPEUTICS, INC.
SALE
Chief Executive Officer
12,9001,763,968Nov 21, 2024Nov 21, 2024View →
CADL
CANDEL THERAPEUTICS, INC.
SALE
Chief Executive Officer
22,528$6.47$145.8K330,735Jul 17, 2024Jul 19, 2024View →
CADL
CANDEL THERAPEUTICS, INC.
SALE
Chief Executive Officer
20,293$5.97$121.2K353,263Jul 11, 2024Jul 15, 2024View →
CADL
CANDEL THERAPEUTICS, INC.
SALE
Chief Executive Officer
43,443$0.90$39.1K373,556Nov 28, 2023Nov 30, 2023View →
CADL
CANDEL THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
180,108416,999Nov 26, 2023Nov 28, 2023View →
CADL
CANDEL THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
180,000180,000Apr 28, 2023May 2, 2023View →
CADL
CANDEL THERAPEUTICS, INC.
PURCHASE
Chief Executive Officer
12,935$1.92$24.8K40,985Dec 9, 2022Dec 12, 2022View →
CADL
CANDEL THERAPEUTICS, INC.
PURCHASE
Chief Executive Officer
3,050$1.70$5.2K28,050Dec 8, 2022Dec 12, 2022View →
CADL
CANDEL THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
195,906220,906Nov 28, 2022Nov 30, 2022View →
CADL
CANDEL THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
330,000330,000Feb 28, 2022Mar 1, 2022View →
CADL
CANDEL THERAPEUTICS, INC.
PURCHASE
Chief Executive Officer
25,000$8.00$200.0K25,000Jul 29, 2021Aug 2, 2021View →
Other insiders · CADL
Loading peer insiders…
About this filer
CIK 0001873905
ROLE
Chief Executive Officer
PRIMARY
CADL
COMPANIES
1
ACTIVE SINCE
Jul 2021
MARKETPEEL · /INSIDER/0001873905DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback